NCT01042379 2026-03-13
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
Clinical Trials
12 trialsNCT04829604 2026-03-09
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Ambrx, Inc.
Phase 2 Active not recruiting
NCT06224673 2026-02-13
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
University of California, San Francisco
Phase 2 Not yet recruiting
NCT05426486 2024-10-30
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2/3 Active not recruiting
NCT06663748 2024-10-29
ARX788 in HER2-positive Metastatic Breast Cancer Patients
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT06578286 2024-08-29
ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Fudan University
Phase 2 Not yet recruiting
NCT03255070 2024-02-01
A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)
Ambrx, Inc.
Phase 1 Completed
NCT04983121 2022-09-13
Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
Shengjing Hospital
Phase 2 Recruiting
NCT05041972 2022-09-13
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Ambrx, Inc.
Phase 2 Withdrawn
NCT05018702 2022-06-01
ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases
Fudan University
Phase 2 Unknown
NCT05018676 2022-04-25
ARX788 in Breast Cancer With Low Expression of HER2
Fudan University
Phase 2 Unknown
NCT02512237 2020-06-05
A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression
Zhejiang Medicine Co., Ltd.
Phase 1 Terminated